<sup>177</sup>Lu-PSMA Radioligand Therapy for Prostate Cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28663195.
- Also identified by DOI 10.2967/jnumed.117.191023.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<sup>177</sup>Lu-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) using inhibitors of PSMA is a novel therapeutic option in patients with metastatic castration-resistant prostate cancer. The current literature suggests that this therapy is well tolerated and effective. On the basis of clinical need and current evidence, the therapy is being implemented in a growing number of centers worldwide. Here, we review important aspects of <sup>177</sup>Lu-PSMA RLT, including patient stratification, the therapy protocol, concomitant medication, and follow-up, to inform medical staff involved in the RLT and care of patients with metastatic castration-resistant prostate cancer.
Medical subject headings
- Antigens, Surface
- Glutamate Carboxypeptidase II
- Lutetium
- Prostatic Neoplasms
- Radioisotopes
- Radiotherapy